Tiffanie McDowell
Areas of Focus
Overview
Tiffanie McDowell is a partner in Crowell & Moring's Orange County office, where she practices in the firm's Antitrust and Competition Group and Health Care groups. Her practice focuses primarily on complex antitrust litigation, pharmaceutical advertising, pricing and access issues, and health care recovery.
Career & Education
- University of Missouri, B.S., cum laude, political science, 2006
- University of Missouri, B.A., cum laude, international studies, 2006
- University of Missouri, B.B.A., cum laude, international business, 2006
- University of San Diego School of Law, J.D., Academic Scholarship, cum laude, 2012
- University of San Diego School of Law, LL.M., Dean's Academic Scholarship, cum laude, taxation, 2014
- California
Tiffanie's Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Speaking Engagement | 03.04.26
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
Insights
Tripped at Customs: EU Seizures of Indian Generic Pharmaceutical Drugs in Transit
|08.19.15
Practitioner Treatise on International Business Vol. 2, Ralph Folsom ed.
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
“Partnering to Maximize and Regularize Returns,” Twelfth Annual In-House Recovery Conference, Dana Point, CA
|03.04.26
Industries
Tiffanie's Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Speaking Engagement | 03.04.26
“Navigating Challenges in the Pharmaceutical Antitrust Landscape,” Twelfth Annual In-House Recovery Conference, Dana Point, CA




